Lilly CEO shades amylin rivals AbbVie, Pfizer in cutthroat battle for obesity’s next act

Amylin drugs have become the next big thing in obesity. Eli Lilly CEO David Ricks, understandably, thinks his rivals don’t have a chance for one key reason.